<DOC>
	<DOC>NCT00670553</DOC>
	<brief_summary>The purpose of this study is to assess the feasibility of combined administration of different LBH589 dosages with radiotherapy in order to establish the dosage to be evaluated in future studies.</brief_summary>
	<brief_title>A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Inclusion criteria: Patients with age â‰¥18 years Confirmed diagnosis of prostate cancer, SCC esophageal cancer or head &amp; neck cancer No evidence of distant spread of the disease Exclusion criteria: Patients who have severe and/or uncontrolled medical conditions Female patients who are pregnant or breast feeding Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Prostate,</keyword>
	<keyword>Head &amp; Neck,</keyword>
	<keyword>Esophageal</keyword>
</DOC>